ACCELERATED PUBLICATION

Hepatically derived selenoprotein P is a key factor for kidney but not for brain selenium supply

Ulrich SCHWEIZER*†[1], Florian STRECKFUß*†, Paco PELT*†, Bradley A. CARLSON‡, Dolph L. HATFIELD‡, Josef KÖHRLE† and Lutz SCHOMBURG†

*Neurobiologie des Selens, Neurowissenschaftliches Forschungzentrum, Charité – Universitätsmedizin Berlin, Schumannstrasse 20/21, 10117 Berlin, Germany, †Institut für Experimentelle Endokrinologie, Charité – Universitätsmedizin Berlin, 10117 Berlin, Germany, and ‡Molecular Biology of Selenium Section, Laboratory of Cancer Prevention, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, U.S.A.

Liver-specific inactivation of *Trsp*, the gene for selenocysteine tRNA, removes SePP (selenoprotein P) from plasma, causing serum selenium levels to fall from 298 μg/l to 50 μg/l and kidney selenium to decrease to 36 % of wild-type levels. Likewise, glutathione peroxidase activities decreased in plasma and kidney to 43 % and 18 % respectively of wild-type levels. This agrees nicely with data from SePP knockout mice, supporting a selenium transport role for hepatically expressed SePP. However, brain selenium levels remain unaffected and neurological defects do not occur in the liver-specific *Trsp* knockout mice, while SePP knockout mice suffer from neurological defects. This indicates that a transport function in plasma is exerted by hepatically derived SePP, while in brain SePP fulfils a second, hitherto unexpected, essential role.

Key words: brain, glutathione peroxidase, selenium, selenocysteine, selenoprotein P, tRNA[Ser]Sec.

INTRODUCTION

Se (selenium) is an essential micronutrient in the diet of humans and other mammals, and has numerous health effects [1]. It occurs in proteins in the form of the unusual amino acid Sec (selenocysteine). Sec-containing proteins, designated selenoproteins, are likely to account for many of the health benefits derived from Se. The human genome contains 25 genes encoding selenoproteins [2]; among these, the GPxs (glutathione peroxidases) [3,4], thioredoxin reductases [5] and thyroid hormone deiodinases [6] are the best characterized. Sec is co-translationally incorporated into the growing polypeptide chain in response to an in-frame UGA codon. In eukaryotes, the presence of a specific RNA stem-loop structure in the 3′-untranslated region of the mRNA recodes the opal STOP codon to dictate Sec incorporation (see [7] for a review).

SePP (selenoprotein P) is a unique selenoprotein, in that it is the only such protein known that contains multiple Sec residues; it may carry between 10 and 17 Sec moieties depending on the species. More than 50 % of plasma Se exists in SePP, suggesting a role for this protein in Se transport [8]. Gene targeting of SePP leads to a substantial decrease in Se levels in plasma, kidney, testis, heart and brain which is associated with subsequent decreases in selenoenzyme activities in these organs [9,10]. Supplementation of SePP KO (knockout) mice with Se-containing compounds restored tissue Se levels and selenoenzyme activities [11,12], further supporting a transport role for SePP. SePP mRNA expression is highest in the liver, but most other organs, including brain, also express SePP mRNA. The brain is a privileged organ with respect to Se supply, suggesting a vital role for selenoproteins in brain function [13]. Accordingly, dietary Se depletion and gene targeting of individual selenoproteins have provided evidence for specific roles of selenoproteins in brain function [14]. For example, SePP KO mice display a neurological phenotype with a movement disorder and epileptic seizures associated with greatly decreased brain Se content [9,11,12]. Maintaining rodents on a Se-deficient diet for several generations has not achieved the same decrease in brain Se content, nor has it led to spontaneous neurological phenotypes like those observed in SePP KO mice [15].

Therefore we wondered whether the liver is the sole source of the plasma SePP pool distributing Se within the body, or whether SePP may also have specific local functions in other organs. We took advantage of our SePP KO mice and compared them with mice lacking the *Trsp* (tRNA[Ser]Sec) gene only in the liver [16]. Without a functional *Trsp* gene in hepatocytes, these mice are unable to synthesize and secrete hepatic selenoproteins into the circulatory system. We show that liver-specific gene targeting of *Trsp* greatly decreases plasma SePP and thereby plasma Se levels, leading to similar impairments of renal GPx expression as described in SePP KO mice. However, the neurological dysfunction present in SePP KO mice was not replicated in liver-specific *Trsp* KO mice, a finding that strongly suggests an additional, hitherto unrecognized, local role of SePP in the brain.

MATERIALS AND METHODS

Animals

Mice that were homozygous for the floxed tRNA[Ser]Sec gene (*Trsp*^fl/fl^) and heterozygous for *Alb-Cre* (an albumin–Cre transgene), wherein the *Cre* recombinase is driven by the

---

hepatocyte-specific albumin promoter and $Trsp^{fl/fl}$ is targeted for removal in the liver, were described recently [16]. Animals were maintained in a 12 h/12 h light/dark cycle with free access to food and water as described [9] and fed with standard lab chow (Altromin, Lage, Germany). Blood was taken after killing by cardiac puncture and treated or not with heparin, and plasma and serum were prepared after centrifugation at 10 000 g at 4 °C for 10 min and frozen at −80 °C.

Testing of motor co-ordination on the rotarod was performed as described in [11]. For footprint analysis, stamp pad ink was applied to front (red) and back (black) paws and the animal was placed on a paper-covered path leading to a dark box. Stride length for front and back paws as well as the base width (i.e. the distance between the two hindpaw footprints) were determined for each animal at least three times. Results comparing base widths showed the same pattern and significance as those for stride length, and are available upon request. Animal studies were conducted according to legal regulations and approved by the local authorities in Berlin, Germany.

Se determinations

Se measurements were performed by a fluorimetric assay as described [11]. A commercial Se standard (Aldrich #247928; Sigma, Munich, Germany) and an independent seronorm standard (Sero AS, Billingstad, Norway) were used as reference samples to verify the assay.

Enzymatic assay

Enzymatic activity of eGPx (extracellular GPx) was determined using mouse plasma samples as described in [11]. cGPx (cellular GPx) activity was determined in tissue homogenates prepared as described in [9]. In brief, NADPH consumption by glutathione reductase was monitored at 340 nm as a measure of the GSSG formation catalysed by GPx. Enzymatic activity was recorded at 37 °C in a buffer containing 0.02 M potassium phosphate, pH 7.0, 0.6 mM EDTA, 0.15 mM NADPH, 2 mM GSH and 4 units of glutathione reductase (Calbiochem, Darmstadt, Germany). The reaction was started by addition of t-butylhydroperoxide (0.1 mM final concentration) as substrate. Background NADPH consumption was determined in the presence of 100 mM mercaptosuccinate and subtracted. Protein concentration was determined by the method of Bradford using IgG as a standard.

Northern blot analysis

cDNA fragments encompassing the complete reading frames of murine SePP, cGPx and eGPx were amplified by PCR, subcloned into pGEM-T vectors (Promega, Mannheim, Germany) and verified by DNA sequencing (BigDye Termination Sequencing Kit; Applied Biosystems, Warrington, U.K.). The inserts were prepared by restriction digestion and preparative gel electrophoresis, and radioactively labelled with [^{32}P]dCTP (Hartmann Analytic, Braunschweig, Germany) using a random priming kit (High Prime; Roche Diagnostics GmbH, Mannheim, Germany). Hybridizations were conducted essentially as described in [9], and specific signals were quantified employing a phosphoimager (Cyclon; Perkin Elmer, Köln, Germany). Signals for GAPDH (glyceraldehyde-3-phosphate dehydrogenase) were subsequently recorded and used to calculate relative changes in transcript levels.

Western blot analysis

Aliquots of 50 μg of liver homogenates were separated by SDS/PAGE (10 % polyacrylamide gel), and polyclonal antibodies against mouse SePP were used as described [11].

Figure 1   Reduced SePP expression in liver-specific selenoprotein KO mice

(**A**) Serum Se levels in male mice at 5 weeks of age. The following genotypes were analysed: $Trsp^{fl/fl}$ and $Trsp^{fl/+}$ ($n = 14$), $Alb\text{-}Cre$; $Trsp^{fl/+}$ ($n = 10$), and $Alb\text{-}Cre$; $Trsp^{fl/fl}$ ($n = 8$). Significant difference compared with wild type: ***$P < 0.001$ (one-way ANOVA with Dunnett's *post hoc* test). (**B**) Western blot reveals a marked decrease in SePP expression in livers from liver-specific selenoprotein KO mice. Samples from individual mice of the indicated genotypes are shown. Serum served as a positive control for SePP. Positions of marker proteins in kDa are indicated.

RESULTS

Reduced plasma Se levels in liver-specific selenoprotein KO mice

$Trsp$ was selectively removed from the hepatocytes of mice ($Alb\text{-}Cre$; $Trsp^{fl/fl}$; referred to herein as liver-specific selenoprotein KO mice) using $Cre\text{-}loxP$ technology as described in the Materials and methods section. These mice were analysed at the age of 5 weeks, i.e. the age at which SePP KO mice were analysed previously in our lab [9,11]. At this age and under our housing conditions, liver-specific selenoprotein KO mice did not show any signs of illness, and we used them, in first approximation, as a model for liver-specific SePP KO mice. In order to determine the contribution of the liver to plasma Se content, we compared liver-specific selenoprotein KO mice with appropriate littermate controls that encoded $Trsp$ as either $Trsp^{fl/fl}$ or $Trsp^{fl/+}$. As shown in Figure 1(A), there was a marked decrease in plasma Se concentration in the liver-specific selenoprotein KO mice. Synthesis of SePP, the main plasma Se carrier, is almost absent in the liver of these mice (Figure 1B). The remaining plasma Se content was the same as in SePP KO mice [9], suggesting that SePP secreted by the liver is the main determinant of plasma Se levels. Although most organs are known to express SePP mRNA, they obviously do not contribute significantly to plasma SePP levels.

Impaired expression of GPx in kidney

The other major selenoprotein in plasma is eGPx (plasma GPx). We determined eGPx activity in plasma from liver-specific selenoprotein KO mice and littermate controls (Figure 2A). Again, eGPx activity was decreased by approx. 50 % in liver-specific

**Figure 2   Kidney selenoprotein expression depends on liver-derived SePP**

(**A**) eGPx activity was measured in the plasma of 5-week-old male mice. The following genotypes were analysed: $Trsp^{fl/fl}$ and $Trsp^{fl/+}$ ($n = 8$), Alb-Cre; $Trsp^{fl/+}$ ($n = 10$), and Alb-Cre; $Trsp^{fl/fl}$ ($n = 7$). (**B**) cGPx activity was determined in kidney homogenates with t-butylhydroperoxide as a substrate (male mice; $n = 6$–9). Wild-type ($Trsp^{fl/fl}$ and $Trsp^{fl/+}$) GPx activity was 516 $\pm$ 60 nmol of NADPH/min per mg of protein. Significant differences compared with wild type: ***$P < 0.001$ (one-way ANOVA with Dunnett's *post hoc* test).

Table 1   Se content in liver-specific selenoprotein KO mice

Measurements were performed using 5-week-old male mice. Values are means $\pm$ S.E.M. ($n = 6$–9). *$P < 0.05$, **$P < 0.01$ compared with control ($Trsp^{fl/fl}$ and $Trsp^{fl/+}$) (one-way ANOVA with Dunnett's test).

	Se content (ng/mg of protein)		
Organ	$Trsp^{fl/fl}$ and $Trsp^{fl/+}$	Alb-Cre; $Trsp^{fl/+}$	Alb-Cre; $Trsp^{fl/fl}$
Kidney	2.5 $\pm$ 0.4	2.1 $\pm$ 0.3	0.9 $\pm$ 0.2*
Liver	2.5 $\pm$ 0.4	2.4 $\pm$ 0.3	0.9 $\pm$ 0.3**
Brain	1.1 $\pm$ 0.2	0.9 $\pm$ 0.3	0.8 $\pm$ 0.3

selenoprotein KO mice, as in SePP-deficient mice [11]. The main site of eGPx secretion into plasma is the kidney [17]. We have shown previously that the reduced renal GPx activity observed in SePP KO mice can be rescued by Se supplementation, suggesting that kidney selenoprotein and Se levels depend on Se provided by the circulatory system [11]. Accordingly, renal GPx activity, as a measure for Se bioavailability in kidney, was drastically decreased in liver-specific selenoprotein KO mice (Figure 2B). This nicely parallels the reduced kidney Se content (Table 1). Since we found almost exactly the same decrease in renal GPx activity in liver-specific selenoprotein KO and SePP KO mice [9], the impairment of renal Se availability is likely to be caused by the lack of hepatically derived SePP.


Figure 3   Selenoprotein transcript levels are not altered in kidneys from liver-specific selenoprotein KO mice

(**A**) Northern blot analysis of eGPx, cGPx and SePP mRNAs. GAPDH was used as a standard. One representative Northern blot from two independent experiments is shown. Levels were measured in kidneys from 5-week-old male mice ($n = 5$–6). (**B**) Quantification of selenoprotein mRNA expression. Phosphorimager signals were normalized using GAPDH. Results for liver-specific selenoprotein KO mice are expressed as a fraction of those for wild-type (wt) littermate controls. n.s., not significant (Student's *t* test).

In order to test whether GPx down-regulation in liver-specific selenoprotein KO mice occurs at the transcript level, we performed Northern blot experiments on kidneys from these mice. As in SePP-deficient mice, there was no difference in the amounts of renal eGPx transcripts between liver-specific selenoprotein KO mice and controls (Figure 3). This implies that renal eGPx expression is subject to translational control, possibly depending on the supply of Sec-tRNA[Ser]Sec. In summary, liver-specific selenoprotein KO mice resemble SePP KO mice with respect to decreased plasma and kidney Se levels and diminished renal GPx expression.

Brain-specific function of SePP

We and others have reported that SePP KO mice display a neurological phenotype involving seizures and a movement disorder [9,10,12]. According to a transport hypothesis for the physiological role of SePP, it appeared conceivable that the neurological dysfunction as well as decreased selenoenzyme activities in the brains of SePP KO mice resulted from impaired Se transport from the liver to the brain. This was believed to be mediated by the lack of plasma SePP, resulting in a drastically reduced Se concentration in plasma. However, liver-specific selenoprotein KO mice do not suffer from seizures, and nor could we observe any abnormal behaviour, despite markedly decreased plasma Se levels. Unlike SePP KO mice, their rotarod performance was indistinguishable from that of littermate controls (Figure 4A). In addition, footprint analyses did not reveal an abnormal gait of these mice, although SePP KO mice had a reduced stride length as assessed by this assay (Figure 4B). Se content in brains from liver-specific selenoprotein KO mice was unaltered (Table 1). In these mice, cGPx activity,

Figure 6   Summary of proposed function for SePP in Se transport and storage

The current model states that dietary Se compounds are taken up by the liver, where selenoproteins, including SePP, are synthesized. SePP is secreted into plasma and provides Se to the rest of the body. The kidney takes up liver-derived SePP from plasma for biosynthesis of selenoproteins, including eGPx. A similar scenario was expected for brain. However, in the absence of hepatic selenoprotein biosynthesis, plasma SePP and plasma Se levels are severely reduced, but brain selenoprotein metabolism remains unaffected, indicating an alternative route for Se uptake available to the brain. We propose SePP to also serve as a local Se storage and recycling protein. All available Se not needed to maintain selenoenzyme activities is incorporated into SePP to serve as an extracellular Se store. After proteolytic cleavage, the Se-rich C-terminus is taken up by the neuron and re-used for selenoprotein biosynthesis. Thus genetic inactivation of SePP compromises brain selenoprotein metabolism and Se retention, while liver-specific inactivation of SePP does not affect brain Se status, selenoprotein biosynthesis or Se retention.

**Figure 4   Unlike SePP KO mice, liver-specific selenoprotein KO mice do not display a movement disorder**

(**A**) Rotarod analysis. No differences in motor co-ordination were observed between genotypes $Trsp^{fl/fl}$ and $Trsp^{fl/+}$ ($n = 21$), $Alb\text{-}Cre; Trsp^{fl/+}$ ($n = 12$), and $Alb\text{-}Cre; Trsp^{fl/fl}$ ($n = 15$). (**B**) Footprint analysis. Stride length is compared between SePP KO mice, SePP KO mice rescued with selenite from birth (1 μM or 10 μM in drinking water) and liver-specific selenoprotein KO mice. Selenite supplementation dose-dependently leads to amelioration of the movement disorder of SePP KO mice, while liver-specific selenoprotein KO mice are indistinguishable from wild-type mice. Results from wild-type littermate controls of each group were similar. ($n = 4$–6). Significance of differences: n.s. not significant; $*P < 0.05$; $***P < 0.001$ (one-way ANOVA with Dunnett's *post hoc* test).

Figure 5   Brain GPx activity is unaltered in liver-specific selenoprotein KO mice

GPx activity was determined in brain homogenates from 5-week-old mice with t-butylhydroperoxide as a substrate. The following genotypes were analysed: $Trsp^{fl/fl}$ and $Trsp^{fl/+}$ ($n = 16$), $Alb\text{-}Cre; Trsp^{fl/+}$ ($n = 12$), and $Alb\text{-}Cre; Trsp^{fl/fl}$ ($n = 16$).

a sensitive marker of tissue Se levels, was also unchanged (Figure 5). We conclude from these findings that the brain can maintain its Se and selenoenzyme levels in the absence of hepatic SePP

production, and thus is largely independent of plasma Se levels as long as local SePP expression in brain is preserved. Our results thus provide the first direct evidence for a physiological function for local SePP expression in brain, distinct from its role as a plasma Se carrier.

DISCUSSION

The current model of Se distribution within the body states that dietary Se after intestinal absorption is taken up by the liver, where it is transformed and incorporated into selenoproteins, including SePP [18]. SePP in turn is secreted into plasma to serve as a Se transport protein supplying Se to the other organs (Figure 6). Several lines of evidence support this model: (1) mammalian SePP contains the unusual number of 10–12 Sec residues, none of which (with one exception) have been implicated in any enzymatic mechanism; (2) plasma SePP is a marker for dietary Se status [19]; (3) for cultured cells, SePP is a bioavailable source of Se [20,21], and its Sec-rich C-terminus can be liberated specifically by proteolytic cleavage [22]; (4) ^{75}Se-labelled SePP injected into rats is taken up readily by other tissues, including the brain, in contrast with ^{75}Se-labelled cGPx [23]; (5) genetic inactivation of SePP in mice results in greatly diminished plasma Se levels and decreased Se content in kidney, testis, heart and brain [9,10]; and (6) supraphysiological Se supplementation of SePP KO mice

rescues their biochemical and neurological phenotype [11,12]. Here we report that liver-specific inactivation of selenoprotein biosynthesis leads to a loss of SePP in plasma and a significant decrease in plasma Se content that resembles the situation in SePP KO mice. Similarly, kidney GPx activity, a sensitive measure of Se bioavailability, is greatly diminished in liver-specific seleno-protein KO mice, as is renal secretion of eGPx. In addition, our data suggest that, despite SePP mRNA expression in other organs, these organs do not contribute significantly to plasma SePP or Se levels. Thus our data seemingly support the current model of Se transport from the liver via SePP to other organs.

However, brain selenoprotein biosynthesis is not impaired in liver-specific selenoprotein KO mice, and no neurological pheno-type is observed, in contrast with SePP KO mice. This finding hints at a hitherto less appreciated role of local SePP expression in the brain. Obviously, the brain can maintain its Se status even in the absence of liver-derived plasma SePP and reduced Se levels in plasma, provided that SePP expression is preserved inside the brain. Likewise, in rats bred and maintained on a Se-deficient diet for generations, plasma and liver Se levels decrease drastically, while normal brain Se levels are maintained [24]. The lack of SePP expression in the brain is apparently more deleterious than its lack in the liver or plasma (or both). Interest-ingly, SePP has been purified as a neurotrophic activity from bovine serum [20]. Several investigators have found SePP mRNA in human [25], mouse [9] and bovine [26] brain, and in cultured brain cells [27]. Thus Se could be organified and concen-trated within the brain via local SePP biosynthesis. However, the pertinent question is what role SePP plays for neurons. It may harbour a neuroprotective activity, e.g. it may act as a peroxy-nitrite scavenger [28], as a Hg- and Cd-detoxifying protein [29] or as a phospholipid hydroperoxide peroxidase [30]. These hypo-theses, however, have so far not been supported by *in vivo* experiments. For example, Se supplementation of SePP KO mice normalizes the neurological condition – this would not be possible if the SePP KO phenotype is caused by lack of a specific activity related to SePP protein other than Se transport or storage. In the light of our new findings, we propose a novel role for SePP as a local Se organifier and an extracellular Se storage protein. Owing to their inherent reactivity, Se compounds are potentially hazardous thiol-modifying agents. Therefore Sec is not a storage form for Se, and nor is it directly charged on to tRNA[Ser]Sec. We hypothesize that available Se is incorporated safely into SePP, which can be exported into the extracellular space for storage. Hence SePP could be taken up by cells at times of need in order to recycle its Se for selenoprotein synthesis (Figure 6). The only missing component would then be a receptor for SePP. The existence of such a receptor has been proposed based on bio-chemical experiments [23,31], but thus far it has not been cloned. Our new model is consistent with SePP being a survival-promoting factor and a form of Se that is more bioavailable than selenite for neurons [20]. This model could also explain why the brain does not lose its Se during times of dietary Se restriction [24], because it implies that Se is trapped within a 'selenoprotein cycle' within the brain [32]. Accordingly, SePP KO mice, initially rescued with selenite, lose their serum Se within 10 days after discontinuation of supraphysiological Se supplementation and start to develop the neurological phenotype after a few weeks. Hence Se loss occurs from the brain in the absence of SePP, even if a Se-adequate diet is provided (U. Schweizer, J. Köhrle and L. Schomburg, unpublished work). Selenocysteine β-lyase (Scly) could close this cycle, as it specifically liberates Se from Sec [33]. Such an enzyme would not be necessary if the Se liberated was not destined for selenoprotein re-synthesis, because Sec is also a substrate for common cysteine desulphurases. Finally, our

hypothesis does not exclude any of the proposed 'moonlighting' activities of SePP that may be of importance when aging beyond the life span of a rodent is considered.

A functional dichotomy between plasma and brain transport protein expression is reminiscent of the iron transport protein transferrin, which is expressed by the liver (representing a source of plasma transferrin), but is also expressed in the brain [34].

Our finding that brain Se levels can be maintained in liver-specific selenoprotein KO mice implies that brain Se levels and plasma Se levels are not necessarily a function of each other – in other words, plasma Se measurements cannot be taken as a meas-ure of brain Se status, but rather represent a measure of hepatic Se status. Thus clinical studies where plasma Se is used as a surrogate marker for brain selenoprotein activity in neurodegener-ative disease should be interpreted with due caution (see [35] for a review). The evaluation of SePP content in cerebrospinal fluid should represent a superior measure of brain Se status, because it is likely to reflect the brain's ability to accumulate Se and synthesize SePP and other essential selenoproteins in sufficient amounts for proper brain functioning.

REFERENCES

1 Rayman, M. P. (2000) The importance of selenium to human health. Lancet **356**, 233–241

2 Kryukov, G. V., Castellano, S., Novoselov, S. V., Lobanov, A. V., Zehtab, O., Guigo, R. and Gladyshev, V. N. (2003) Characterization of mammalian selenoproteomes. Science **300**, 1439–1443

3 Brigelius-Flohé, R. (1999) Tissue-specific functions of individual glutathione peroxidases. Free Radical Biol. Med. **27**, 951–965

4 Arthur, J. R. (2000) The glutathione peroxidases. Cell. Mol. Life Sci. **57**, 1825–1835

5 Rundlof, A. K. and Arner, E. S. (2004) Regulation of the mammalian selenoprotein thioredoxin reductase 1 in relation to cellular phenotype, growth, and signaling events. Antioxid. Redox Signalling **6**, 41–52

6 Köhrle, J. (2000) The deiodinase family: selenoenzymes regulating thyroid hormone availability and action. Cell. Mol. Life Sci. **57**, 1853–1863

7 Hatfield, D. L. and Gladyshev, V. N. (2002) How selenium has altered our understanding of the genetic code. Mol. Cell. Biol. **22**, 3565–3576

8 Motsenbocker, M. A. and Tappel, A. L. (1982) A selenocysteine-containing selenium-transport protein in rat plasma. Biochim. Biophys. Acta **719**, 147–153

9 Schomburg, L., Schweizer, U., Holtmann, B., Flohé, L., Sendtner, M. and Köhrle, J. (2003) Gene disruption discloses role of selenoprotein P in selenium delivery to target tissues. Biochem. J. **370**, 397–402

10 Hill, K. E., Zhou, J., McMahan, W. J., Motley, A. K., Atkins, J. F., Gesteland, R. F. and Burk, R. F. (2003) Deletion of selenoprotein P alters distribution of selenium in the mouse. J. Biol. Chem. **278**, 13640–13646

11 Schweizer, U., Michaelis, M., Köhrle, J. and Schomburg, L. (2004) Efficient selenium transfer from mother to offspring in selenoprotein-P-deficient mice enables dose-dependent rescue of phenotypes associated with selenium deficiency. Biochem. J. **378**, 21–26

12 Hill, K. E., Zhou, J., McMahan, W. J., Motley, A. K. and Burk, R. F. (2004) Neurological dysfunction occurs in mice with targeted deletion of the selenoprotein P gene. J. Nutr. **134**, 157–161

13 Schweizer, U., Bräuer, A. U., Köhrle, J., Nitsch, R. and Savaskan, N. E. (2004) Selenium and brain function: a poorly recognized liaison. Brain Res. Rev. **45**, 164–178

14 Schweizer, U., Schomburg, L. and Savaskan, N. E. (2004) The neurobiology of selenium: lessons from transgenic mice. J. Nutr. **134**, 707–710

15 Savaskan, N. E., Bräuer, A. U., Kühbacher, M., Eyupoglu, I. Y., Kyriakopoulos, A., Ninnemann, O., Behne, D. and Nitsch, R. (2003) Selenium deficiency increases susceptibility to glutamate-induced excitotoxicity. FASEB J. **17**, 112–114

16 Carlson, B. A., Novoselov, S. V., Kumaraswamy, E., Lee, B. J., Anver, M. R., Gladyshev, V. N. and Hatfield, D. L. (2004) Specific excision of the selenocysteine tRNA[Ser]Sec (Trsp) gene in mouse liver demonstrates an essential role of selenoproteins in liver function. J. Biol. Chem. **279**, 8011–8017

17 Maser, R. L., Magenheimer, B. S. and Calvet, J. P. (1994) Mouse plasma glutathione peroxidase. cDNA sequence analysis and renal proximal tubular expression and secretion. J. Biol. Chem. **269**, 27066–27073

18 Burk, R. F., Hill, K. E. and Motley, A. K. (2003) Selenoprotein metabolism and function: evidence for more than one function for selenoprotein P. J. Nutr. **133**, 1517S–1520S

19 Persson-Moschos, M., Alfthan, G. and Akesson, B. (1998) Plasma selenoprotein P levels of healthy males in different selenium status after oral supplementation with different forms of selenium. Eur. J. Clin. Nutr. **52**, 363–367

20 Yan, J. and Barrett, J. N. (1998) Purification from bovine serum of a survival-promoting factor for cultured central neurons and its identification as selenoprotein-P. J. Neurosci. **18**, 8682–8691

21 Saito, Y. and Takahashi, K. (2002) Characterization of selenoprotein P as a selenium supply protein. Eur. J. Biochem. **269**, 5746–5751

22 Saito, Y., Sato, N., Hirashima, M., Takebe, G., Nagasawa, S. and Takahashi, K. (2004) Domain structure of bi-functional selenoprotein P. Biochem. J. **381**, 841–846

23 Burk, R. F., Hill, K. E., Read, R. and Bellew, T. (1991) Response of rat selenoprotein P to selenium administration and fate of its selenium. Am. J. Physiol. **261**, E26–E30

24 Behne, D., Hilmert, H., Scheid, S., Gessner, H. and Elger, W. (1988) Evidence for specific selenium target tissues and new biologically important selenoproteins. Biochim. Biophys. Acta **966**, 12–21

25 Dreher, I., Schmutzler, C., Jakob, F. and Köhrle, J. (1997) Expression of selenoproteins in various rat and human tissues and cell lines. J. Trace Elem. Med. Biol. **11**, 83–91

26 Saijoh, K., Saito, N., Lee, M. J., Fujii, M., Kobayashi, T. and Sumino, K. (1995) Molecular cloning of cDNA encoding a bovine selenoprotein P-like protein containing 12 selenocysteines and a (His-Pro) rich domain insertion, and its regional expression. Mol. Brain Res. **30**, 301–311

27 Yang, X., Hill, K. E., Maguire, M. J. and Burk, R. F. (2000) Synthesis and secretion of selenoprotein P by cultured rat astrocytes. Biochim. Biophys. Acta **1474**, 390–396

28 Arteel, G. E., Mostert, V., Oubrahim, H., Briviba, K., Abel, J. and Sies, H. (1998) Protection by selenoprotein P in human plasma against peroxynitrite-mediated oxidation and nitration. Biol. Chem. **379**, 1201–1205

29 Yoneda, S. and Suzuki, K. T. (1997) Equimolar Hg-Se complex binds to selenoprotein P. Biochem. Biophys. Res. Commun. **231**, 7–11

30 Saito, Y., Hayashi, T., Tanaka, A., Watanabe, Y., Suzuki, M., Saito, E. and Takahashi, K. (1999) Selenoprotein P in human plasma as an extracellular phospholipid hydroperoxide glutathione peroxidase. Isolation and enzymatic characterization of human selenoprotein P. J. Biol. Chem. **274**, 2866–2871

31 Wilson, D. S. and Tappel, A. L. (1993) Binding of plasma selenoprotein P to cell membranes. J. Inorg. Biochem. **51**, 707–714

32 Schomburg, L., Schweizer, U. and Köhrle, J. (2004) Selenium and selenoproteins in mammals: extraordinary, essential, enigmatic. Cell. Mol. Life Sci. **61**, 1988–1995

33 Mihara, H., Kurihara, T., Watanabe, T., Yoshimura, T. and Esaki, N. (2000) cDNA cloning, purification, and characterization of mouse liver selenocysteine lyase. Candidate for selenium delivery protein in selenoprotein synthesis. J. Biol. Chem. **275**, 6195–6200

34 Burdo, J. R. and Connor, J. R. (2003) Brain iron uptake and homeostatic mechanisms: an overview. Biometals **16**, 63–75

35 Chen, J. and Berry, M. J. (2003) Selenium and selenoproteins in the brain and brain diseases. J. Neurochem. **86**, 1–12